Affiliation:
1. Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, 304022, India
2. Department of Pharmaceutical
Sciences, Mohanlal Sukhadia University, Udaipur, 313001, Rajasthan, India
3. Indore Institute of Pharmacy, Rau,
Indore, 453331, India
Abstract
Abstract:
COVID-19, an extremely transmissible and pathogenic viral disease, triggered a global
pandemic that claimed lives worldwide. To date, there is no clear and fully effective treatment for
COVID-19 disease. Nevertheless, the urgency to discover treatments that can turn the tide has led
to the development of a variety of preclinical drugs that are potential candidates for probative results.
Although most of these supplementary drugs are constantly being tested in clinical trials
against COVID-19, recognized organizations have aimed to outline the prospects in which their
use could be considered. A narrative assessment of current articles on COVID-19 disease and its
therapeutic regulation was performed. This review outlines the use of various potential treatments
against SARS-CoV-2, categorized as fusion inhibitors, protease inhibitors, and RNA-dependent
RNA polymerase inhibitors, which include antiviral drugs such as Umifenovir, Baricitinib, Camostatmesylate,
Nafamostatmesylate, Kaletra, Paxlovide, Darunavir, Atazanavir, Remdesivir, Molnupiravir,
Favipiravir, and Ribavirin. To understand the virology of SARS-CoV-2, potential therapeutic
approaches for the treatment of COVID-19 disease, synthetic methods of potent drug candidates,
and their mechanisms of action have been addressed in this review. It intends to help
readers approach the accessible statistics on the helpful treatment strategies for COVID-19 disease
and to serve as a valuable resource for future research in this area.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Biotechnology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献